The zygosity determination of Japanese twins using a minisatellite core probe.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Tateishi.
Explore the source record for details and available documents.
Isolated growth hormone (GH) deficiency (IGHD) is detected in 1/10 of pituitary dwarfism, but there are only a few reports on IGHD as an autosomal-dominant trait. We found one family with autosomal-dominantly inherited IGHD and examined their pituitary functions and GH genomes. Brothers (9.5 year and 11 year) and their mother (37 year) were diagnosed as having IGHD and their grandmother and uncle also seemed to have IGHD. All of their heights were under "mean-4.0 S.D.". Cerebral tomography of brothers and their mother all showed "empty sella", and GH-releasing hormone (GRH) tests showed no responses of GH not only to bolus intravenous injections but also after repeated intramuscular injections of GRH (100 micrograms/day) for 7 days. Although genetic analysis (Southern blotting method) could not detect any mutations in their GH genomes, the IGHD lesion of them seemed to be pituitary in origin.
Using polymorphic DNA markers, we compared the constitutional and tumor genotypes of patients with multiple endocrine neoplasia type 2A (MEN2 A). We found loss of constitutional heterozygosity at the D22S9 locus in one out of 9 medullary thyroid carcinomas (MTCs). No loss of heterozygosity was detected at 12 other loci in any of the MTCs tested. Loss of heterozygosity at D22S9 and/or D22S1 was also demonstrated in 2 out of 5 pheochromocytomas tested. These results suggest that loss or mutation of a gene on chromosome 22 may play an important role in tumorigenesis in MEN2A.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The electrophysiological effects of intravenous administration of diphenylhydantoin (DPH) (5 mg/Kg, maximum 250 mg) were studied in 20 patients with sinus node dysfunction (SND). DPH shortened spontaneous cycle length (SCL) in 3 patients and lengthened it in 3. Maximum corrected sinus node recovery time (max CSRT) was prolonged in 7 patients and shortened in 3. Estimated sinoatrial conduction time was prolonged in 3 patients and shortened in 2 of 10 patients in whom this measurement was possible. However, these changes were not statistically significant. Neither were there any significant changes in PA, AH and HV intervals nor refractory periods of the atrium, the AV node and the ventricle. DPH prolonged SCL and/or max CSRT in 9 of 20 patients with SND, and it was suggested that DPH has depressant effects on the sinus node in some patients with SND. Thus, this drug should be used with caution in the treatment of ventricular arrhythmias accompanied by sinus node dysfunction.
Explore the source record for details and available documents.
To treat the acute phase of myocardial infarction, nitroglycerin and urokinase were injected directly into the infarct-related coronary artery. Left ventricular ejection fraction and regional ejection changes were significantly preserved in the chronic phase, compared with conventional therapy in patients with obstruction at the same site. Comparing left ventricular function in the acute and chronic phases, left ventricular ejection fraction, regional ejection changes and left ventricular end-diastolic pressure were significantly improved in the chronic phase in patients with reperfusion within 6 hours. On the other hand, in patients who had no reperfusion in either the acute or chronic phase, left ventricular ejection fraction deteriorated in the chronic phase. Even in patients with reperfusion in the acute phase, reocclusion later meant a worse left ventricular ejection fraction in the chronic phase. These results suggest that intracoronary thrombolysis with urokinase within 6 hours gives a good chance of recovery from myocardial damage in patients with myocardial infarction.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The electrophysiological effects of intravenous administration of disopyramide (1.5 mg/kg) were studied in 26 patients with sinus node dysfunction (SND). Disopyramide shortened spontaneous cycle length (SCL) in 12 patients and lengthened it in 4. Maximum sinus node recovery time (max SRT) was prolonged in 9 patients and shortened in 6. Estimated sinoatrial conduction time (SACT) was prolonged in 4 and shortened in 4 out of 10 patients in whom this measurement was possible. However, these changes were not statistically significant. Neither were there any significant changes in PA and AH intervals nor refractory periods of the AV node. HV intervals and refractory periods of the atrium at matched cycle length were significantly lengthened. Atrial echo beats and atrial premature beats disappeared in 7 of 12 patients treated with disopyramide. In all of these 7 patients atrial refractory period were increased. Thus, the disappearance of atrial echo beats and atrial premature beats was thought to be due to a prolonged atrial refractoriness. In 4 patients who had supraventricular arrhythmias without having either marked prolongation of max SRT or episodes of syncope, disopyramide was administered orally for a long term, during which these arrhythmias and symptoms disappeared and sinus rate increased. These results suggest that disopyramide is useful in patients with SND and supraventricular arrhythmias.
Excretion of pivmecillinam (PMPC) in bile was investigated using normal and hepatic disorder (intramuscular injection of carbon tetrachloride, 0.5 g/kg twice) rabbits. Bile and blood were collected hourly (0.5 approximately 8 hours) and both concentrations and rates between both (passage), and excretion rates were investigated. Ampicillin (AMPC) was chosen as a control drug. 1. When PMPC was given orally to the normal rabbit in a dose of 200 mg/kg, a bile concentration after 0.5 hour was 138.08 microgram/ml and a peak value was attained. The rate to plasma concentration was 22.67. An excretion rate was 0.224%. When PMPC was given orally to the hepatic disorder rabbit in a dose of 200 mg/kg, a bile concentration after 0.5 hour was 26.67 microgram/ml. A peak value of 28.87 microgram/ml was attained after 4 hours. Their rates to plasma concentrations were 13.27 and 8.02, respectively. An excretion rate was 0.058%. Bile and plasma concentrations, rates of bile to plasma and excretion rates of the hepatic disorder group were lower than those of the normal group. Disturbances of hepatic functions were checked by biochemical tests, i.e. GOT, and so on. 3. When ABPC as a control drug was given orally to the rabbit in a dose of 200 mg/kg, plasma concentrations of hepatic disorder group were higher than those of the normal group, but rates of bile to plasma concentrations and excretion rates of the hepatic disorder group were lower than those of the normal group. 4. Bile concentrations and excretion of PMPC were significantly higher than those of ABPC in the normal group. In the hepatic disorder group, however, no statistical difference was observed between them.
Explore the source record for details and available documents.
Electrophysiological studies were performed to see the effects of lidocaine on the conduction system, particularly sinus node and atrium in 40 patients of SSS, using HBE recordings, rapid atrial pacing and atrial extrastimulus technique. Sinus cycle length, PA (P'A), AH, HV intervals, calculated SACT, and refractory periods of atrium, AV node and His-Purkinje system did not change after lidocaine. Only maximum CSRT was significantly increased with lidocaine. These results were not affected by pretreatment of atropine. In conclusion, the combining rapid atrial pacing with lidocaine may be useful to manifest the masked sinus node abnormalities. It was suggested that lidocaine directly depressed sinus node automaticity in SSS patients, without affecting perinodal tissue. Therefore, lidocaine should be used with caution in patients with known or suspected SSS.
1) A focal infection was prepared by inoculation of staphylococci into rat gingiva. Then, concentrations in oral tissues (gingiva, tongue and masseter), serum and liver of the infected rats which were given ciclacillin, ampicillin, cephalexin and minocycline in a dose of 100 mg/kg p.o. were investigated and effects of serratiopeptidase (20 mg/kg) on these concentrations were studied. 2) Concentrations of ciclacillin in the oral tissues were approximately 10% of a serum level. A gingival concentration was elevated 8.5-fold by pretreatment with serratiopeptidase. A concentration in infected gingiva was 2.5-fold of that of another side of gingiva. 3) Concentrations of ampicillin in the oral tissues were approximately 15% of a serum level. A gingival concentration was elevated 5.7-fold by pretreatment with serratiopeptidase. A concentration in infected gingiva ws 2.2-fold of that of another side of gingiva. 4) Concentrations of cephalexin in the oral tissues were approximately 3 to 5-fold of a serum level except that in masseter. A gingival concentration was slightly elevated (1.1-fold) by pretreatment with serratiopeptidase. A concentration in infected gingiva was 1.7-fold of that of another side of gingiva. 5) Concentrations of minocycline in the oral tissues were 1.3 to 7.2-fold of a serum level. A gingival concentration was elevated 2.2-fold by pretreatment with serratipeptidase. A concentration in infected gingiva was 3.1-fold of that of another side of gingiva. 6) Gingival concentrations of antibiotics were higher than those of tongue and masseter and serratiopeptidase elevated gingival concentrations.
Explore the source record for details and available documents.